Novel Therapeutics and Upcoming Clinical Trials Targeting Inflammation in Cardiovascular Diseases
Arteriosclerosis, Thrombosis, and Vascular Biology · 2024-12 · 44 (12) · 2371-2395
DOI: 10.1161/atvbaha.124.319980 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2024-12. Verfasst von Nicola Potere und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Ageing Sciences, "G. d'Annunzio" University of Chieti-Pescara, Italy (N.P.). Hauptthemen laut MEDLINE: Cardiovascular Diseases, Anti-Inflammatory Agents, Inflammation. Die Arbeit wurde bisher 84-mal zitiert (Crossref) und nennt 172 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Cardiovascular disease (CVD) remains a major health burden despite significant therapeutic advances accomplished over the last decades. It is widely and increasingly recognized that systemic inflammation not only represents a major cardiovascular risk and prognostic factor but also plays key pathogenic roles in CVD development and progression. Despite compelling preclinical evidence suggesting large potential of anti-inflammatory pharmacological interventions across numerous CVDs, clinical translation remains incomplete, mainly due to (1) yet undefined molecular signaling; (2) challenges of safety and efficacy profile of anti-inflammatory drugs; and (3) difficulties in identifying optimal patient candidates and responders to anti-inflammatory therapeutics, as well as optimal therapeutic windows. Randomized controlled trials demonstrated the safety/efficacy of canakinumab and colchicine in secondary cardiovascular prevention, providing confirmation for the involvement of a specific inflammatory pathway (NLRP3 [NACHT, LRR, and PYD domain-containing protein 3] inflammasome/IL [interleukin]-1β) in atherosclerotic CVD. Colchicine was recently approved by the US Food and Drug Administration for this indication. Diverse anti-inflammatory drugs targeting distinct inflammatory pathways are widely used for the management of other CVDs including myocarditis and pericarditis. Ongoing research efforts are directed to implementing anti-inflammatory therapeutic strategies across a growing number of CVDs, through repurposing of available anti-inflammatory drugs and development of novel anti-inflammatory compounds, which are herein concisely discussed. This review also summarizes the main characteristics and findings of completed and upcoming randomized controlled trials directly targeting inflammation in CVDs, and discusses major challenges and future perspectives in the exciting and constantly expanding landscape of cardioimmunology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Ageing Sciences, "G. d'Annunzio" University of Chieti-Pescara, Italy (N.P.).
- Department of Internal Medicine, Medical Center, S.C. Medicina Generale 1, Ospedale di Circolo and Fondazione Macchi, ASST Sette Laghi Varese, Italy (A.B.).
- Berne Cardiovascular Research Center and Division of Cardiology, University of Virginia, Charlottesville (A.A.).
ORCID-Profile: Nicola Potere, Aldo Bonaventura, Antonio Abbate
Förderung
- NIA NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Potere, N., Bonaventura, A., & Abbate, A. (2024). Novel Therapeutics and Upcoming Clinical Trials Targeting Inflammation in Cardiovascular Diseases. Arteriosclerosis, Thrombosis, and Vascular Biology, 44(12), 2371-2395. https://doi.org/10.1161/atvbaha.124.319980
Vancouver
Potere N, Bonaventura A, Abbate A. Novel Therapeutics and Upcoming Clinical Trials Targeting Inflammation in Cardiovascular Diseases. Arteriosclerosis, Thrombosis, and Vascular Biology. 2024;44(12):2371-2395. doi:10.1161/atvbaha.124.319980
BibTeX
@article{Potere2024,
author = {Potere, Nicola and Bonaventura, Aldo and Abbate, Antonio},
title = {Novel Therapeutics and Upcoming Clinical Trials Targeting Inflammation in Cardiovascular Diseases},
journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
year = {2024},
volume = {44},
number = {12},
pages = {2371--2395},
doi = {10.1161/atvbaha.124.319980}
}
EUVIMED